Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in Korea

Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in Korea

This study evaluated the toxicity profiles of temozolomide in the treatment of malignantglioma as either concurrent or adjuvant chemotherapy. We retrospectively reviewed themedical records of 300 malignant glioma patients treated with temozolomide in twomedical institutions in Korea between 2004 and 2010. Two hundred nine patientsexperienced a total of 618 toxicities during temozolomide therapy. A total of 84.8% of the618 toxicities were Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or 2,while 15.2% were grade 3 or 4. Among the hematologic toxicities, thrombocytopenia(13.7%), anemia (11.0%), and AST/ALT increases (7.0%) were common. Among the nonhematologictoxicities, nausea (44.3%), vomiting (37.0%), and anorexia (14.3%) were thethree most common toxicities. There was no mortality due to temozolomide. Althoughtemozolomide showed many types of toxicities, the majority of the toxicities were tolerableand of lower grade. Gastrointestinal troubles are the most common toxicities in Koreanpatients treated with temozolomide.

This study evaluated the toxicity profiles of temozolomide in the treatment of malignantglioma as either concurrent or adjuvant chemotherapy. We retrospectively reviewed themedical records of 300 malignant glioma patients treated with temozolomide in twomedical institutions in Korea between 2004 and 2010. Two hundred nine patientsexperienced a total of 618 toxicities during temozolomide therapy. A total of 84.8% of the618 toxicities were Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or 2,while 15.2% were grade 3 or 4. Among the hematologic toxicities, thrombocytopenia(13.7%), anemia (11.0%), and AST/ALT increases (7.0%) were common. Among the nonhematologictoxicities, nausea (44.3%), vomiting (37.0%), and anorexia (14.3%) were thethree most common toxicities. There was no mortality due to temozolomide. Althoughtemozolomide showed many types of toxicities, the majority of the toxicities were tolerableand of lower grade. Gastrointestinal troubles are the most common toxicities in Koreanpatients treated with temozolomide.